Drugs / CPGJ602
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03356158 | Nov 2017 → Oct 2018 | colorectal cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04466254 | Dec 2020 → Dec 2021 | colorectal cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPGJ602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04466254 ↗ |
| Modality | Monoclonal antibody | “a recombinant anti-EGFR monoclonal antibody (CPGJ602)” NCT03356158 ↗ |
| Route | Intravenous | “CPGJ602 administered by intravenous infusion” NCT03356158 ↗ |
| Target | EGFR | “anti-EGFR” NCT03356158 ↗ |